全文获取类型
收费全文 | 5484篇 |
免费 | 358篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 163篇 |
妇产科学 | 148篇 |
基础医学 | 955篇 |
口腔科学 | 138篇 |
临床医学 | 483篇 |
内科学 | 1065篇 |
皮肤病学 | 145篇 |
神经病学 | 687篇 |
特种医学 | 306篇 |
外科学 | 593篇 |
综合类 | 24篇 |
一般理论 | 2篇 |
预防医学 | 258篇 |
眼科学 | 72篇 |
药学 | 420篇 |
中国医学 | 2篇 |
肿瘤学 | 371篇 |
出版年
2023年 | 40篇 |
2022年 | 54篇 |
2021年 | 102篇 |
2020年 | 86篇 |
2019年 | 124篇 |
2018年 | 112篇 |
2017年 | 81篇 |
2016年 | 123篇 |
2015年 | 158篇 |
2014年 | 191篇 |
2013年 | 207篇 |
2012年 | 366篇 |
2011年 | 388篇 |
2010年 | 237篇 |
2009年 | 225篇 |
2008年 | 375篇 |
2007年 | 367篇 |
2006年 | 356篇 |
2005年 | 306篇 |
2004年 | 344篇 |
2003年 | 302篇 |
2002年 | 275篇 |
2001年 | 99篇 |
2000年 | 101篇 |
1999年 | 83篇 |
1998年 | 59篇 |
1997年 | 54篇 |
1996年 | 43篇 |
1995年 | 39篇 |
1994年 | 44篇 |
1993年 | 31篇 |
1992年 | 48篇 |
1991年 | 49篇 |
1990年 | 42篇 |
1989年 | 28篇 |
1988年 | 30篇 |
1987年 | 30篇 |
1986年 | 34篇 |
1985年 | 23篇 |
1984年 | 21篇 |
1983年 | 16篇 |
1982年 | 12篇 |
1981年 | 11篇 |
1980年 | 16篇 |
1979年 | 9篇 |
1977年 | 15篇 |
1976年 | 11篇 |
1975年 | 14篇 |
1974年 | 13篇 |
1971年 | 8篇 |
排序方式: 共有5859条查询结果,搜索用时 15 毫秒
1.
We have shown previously that the plant cannabinoid cannabidiol (CBD) elevates intracellular calcium levels in both cultured hippocampal neurones and glia. Here, we investigated whether the main psychotropic constituent of cannabis, Δ9-tetrahydrocannabinol (THC) alone or in combination with other cannabis constituents can cause similar responses, and whether THC affects the responses induced by CBD. Our experiments were performed with 1 μM pure THC (pTHC), with 1 μM pure CBD (pCBD), with a high-THC, low CBD cannabis extract (eTHC), with a high-CBD, low THC cannabis extract (eCBD), with a mixture of eTHC and eCBD (THC:CBD = 1:1) or with corresponding ‘mock extracts’ that contained only pTHC and pCBD mixed in the same proportion as in eTHC, eCBD or the 1:1 mixture of eTHC and eCBD. 相似文献
2.
3.
Prof. Dr. Alexander Kapp Prof. Dr. Bettina Wedi 《Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete》2006,57(10):854-854
Ohne Zusammenfassung 相似文献
4.
5.
Dimmeler Stefanie; Tonn Torsten; Seeger Florian; Zeiher Andreas M. 《European heart journal》2007,28(17):2175
It obviously escaped the notion of Egeland and Brinchman thatthe protocols additionally differ with regard to the washingsteps and buffer components used in the 相似文献
6.
7.
F Reichenberger R Voswinckel B Enke M Rutsch E El Fechtali T Schmehl H Olschewski R Schermuly N Weissmann H A Ghofrani F Grimminger E Mayer W Seeger 《The European respiratory journal》2007,30(5):922-927
For chronic thromboembolic pulmonary hypertension not amenable to pulmonary endarterectomy, effective medical therapy is desired. In an open-label uncontrolled clinical trial, 104 patients (mean +/- sem age 62 +/- 11 yrs) with inoperable chronic thromboembolic pulmonary hypertension were treated with 50 mg sildenafil t.i.d. At baseline, patients had severe pulmonary hypertension (pulmonary vascular resistance 863 +/- 38 dyn.s.cm(-5)) and a 6-min walking distance of 310 +/- 11 m. Eight patients were in World Health Organization functional class II, 76 in class III and 20 in class IV. After 3 months' treatment, there was significant haemodynamic improvement, with reduction of pulmonary vascular resistance to 759 +/- 62 dyn.s.cm(-5). The 6-min walking distance increased significantly to 361 +/- 15 m after 3 months' treatment, and to 366 +/- 18 m after 12 months' treatment. A subset of 67 patients received a single dose of 50 mg sildenafil during initial right heart catheterisation. The acute haemodynamic effect of this was not predictive of long-term outcome. In this large series of patients with inoperable chronic thromboembolic pulmonary hypertension, open-label treatment with sildenafil led to significant long-term functional improvement. The acute effect of sildenafil may not predict the long-term outcome of therapy. 相似文献
8.
Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)
下载免费PDF全文
![点击此处可从《Neuropsychiatric Disease and Treatment》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Rufinamide, a triazole derivative that is structurally distinct from currently marketed antiepileptic drugs (AEDs), is in development for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in children and adults. Rufinamide is well absorbed after oral administration, demonstrates low protein binding, and is metabolized by enzymatic hydrolysis without involvement of cytochrome P450 enzymes, conferring a low drug interaction potential. In a randomized, double-blind trial involving 138 adult and pediatric patients with LGS, compared with placebo, rufinamide 45 mg/kg/day resulted in significantly superior reductions in drop attacks (median change −42.5% vs +1.4% with placebo) and total seizures (−32.1% vs −11.7% with placebo), accompanied by significantly higher responder rates. These results are comparable with findings reported for other AEDs in randomized, controlled clinical trials in patients with LGS. Rufinamide produced statistically significant seizure reduction which was maintained during long-term therapy and accompanied by good tolerability. The most frequently reported adverse events from a pooled safety database evaluating short- and long-term therapy were headache (22.9% and 29.5%), dizziness (15.5% and 22.5%) and fatigue (13.6% and 17.7%). Rufinamide therefore presents a favorable efficacy and tolerability profile and is a promising candidate for the adjunctive therapy of LGS. 相似文献
9.
Klaus Rauber Kathrin S. Heidinger Bettina Kemkes-Matthes 《Cardiovascular and interventional radiology》1997,20(3):169-173
Purpose To determine the systemic effects of local fibrinolytic therapy with low-dose recombinant tissue-type plasminogen activator
(rt-PA).
Methods Ten patients received intrathrombal infusion of 20 mg rt-PA and heparin for local thrombolysis and had subsequent percutaneous
transluminal angioplasty (PTA). Eight controls underwent PTA and received heparin alone. We measured t-PA, D-Dimer, and fibrinogen
levels before, directly after, and 20, 40, and 60 min and 24 hr after therapy.
Results In the thrombolysis group the t-PA level peaked immediately after infusion and then declined within 1 hr. D-Dimer increased
and remained elevated, whereas in the control group only t-PA levels increased, and only after 24 hr. Fibrinogen remained
within the normal range in both groups. Eight of ten patients in the thrombolysis group and seven of eight with PTA had clinical
improvement after the procedure.
Conclusions The increase in D-Dimer in the rt-PA group indicates a good local fibrinolytic effect. The fact that fibrinogen levels remained
unchanged indicates that there is a lack of systemic fibrinogenolysis. 相似文献
10.